AL amyloidosis was diagnosed in a 56-year-old woman with spontaneous purpura, macroglossia and hepatomegaly, a serum IgGk monoclonal gammopathy and a 25% plasma cell bone marrow infiltration. She was started on high-dose treatment consisting of four monthly cycles of VID chemotherapy, then underwent a stem cell collection after priming with cyclophosphamide + G-CSF. Myeloablative therapy was with melphalan and busulfan. Hematologic recovery was fast and uncomplicated. At follow-up 22 months from ASCT, the patient shows a complete remission of the clonal plasma cell disorder, normalization of liver size and alkaline phosphatase level and a significant improvement in the signs of vascular and soft tissue amyloid infiltration.
AL amyloidosis is a clonal plasma cell disorder related to multiple myeloma characterized by a deposit of fibrillar aggregates of monoclonal immunoglobulin light chains in vital organs. The disease has a poor prognosis due to damage to heart and kidney caused by the amyloid deposit, so that median survival is no longer than 2 years. 1 An excess of plasma cells with a clonal dominance of one light chain isotype is detected on bone marrow biopsy in the majority of patients and a monoclonal protein with the same light chain isotype is present in the serum or urine of 75% of cases, using a combination of immunofixation and agarose gel electrophoresis. 2 The relationship between AL amyloidosis and multiple myeloma has lead to the widespread use of alkylating agents in the treatment of AL amyloidosis. 3 Intermittent oral melphalan and prednisone were able to reduce the plasma cell clone and improve the function of damaged organs in a few patients, but the response rate was low and median survival did not differ from that seen in untreated patients in a recently published randomized trial. 4 However, Correspondence: Dr F Patriarca, Division of Haematology, Udine University Hospital, P le S Maria della Misericordia, 33100 Udine, Italy Received 29 December 1998; accepted 11 March 1999 since it is likely that there is a relationship between improvement in amyloidosis symptoms and decrease of the plasma cell burden, high-dose treatment with hemopoietic progenitor support has been investigated in the last 5 years in patients with AL amyloidosis. We report the case of a patient who underwent autotransplantation, and entered complete remission from the clonal disorder with improvement in the typical amyloid-related symptoms.
Case report
In December 1994, a 56-year-old woman presented to our centre. She had been suffering from arthralgia of the shoulders, wrists, hands, fingers and hips for 1 year and complained of easy bruising and dysphagia for several months. Surgical decompression of both median nerves for bilateral carpal syndrome was carried out without improving pain in her wrists and hands. The patient had spontaneous periorbital purpura, conjuntival injection of both eyes, ecchymosis of the anterior chest, swelling of lips and fingers and macroglossia ( Figure 1 ). She spoke with a weak voice and her liver was palpable 4 cm below the right costal margin. She complained of paresthesias in the upper limbs, but power and reflexes were normal.
Hematologic and clotting values were normal. Serum electrophoresis showed an IgGk monoclonal gammopathy: the serum total protein concentration was 70 g/l, serum IgG level was 12 g/l and polyclonal immunoglobulin were not depressed. The serum alkaline phosphatase was 255 U/l (normal value Ͻ112) and serum creatinine was normal. Urine analysis showed a 24 h protein excretion of 0.5 g with minimal amounts of Bence-Jones proteinuria. A skeletal survey demonstrated no lytic lesions. Bone marrow biopsy showed a 25% plasma cell infiltration with dominance, identified by immunohistochemical staining. Amyloid deposits on Congo red staining was found in the tongue, bone marrow and peri-umbilical biopsies. Electrocardiogram showed diffuse low voltages, but no signs of cardiac involvement was identified. Indirect laryngoscopy demonstrated swelling of the vocal cords.
The patient was treated with a standard-dose regimen consisting of four monthly cycles of VID (vincristine 0. + cells after two aphereses. Plasma cell contamination in the aphereses was identified by a flow cytometric technique based on the coexpression of BB4(CD138) and CD38 monoclonal antibodies: plasma cells were 0.34 × 10 6 /kg. The arthralgia did not improve after induction and mobilizing therapy and was alleviated only by low dose (25 mg daily) prednisone. Hepatomegaly, dysphagia and easy bruising did not change. The M component decreased to 6 g/l and marrow plasmacytosis was 30%.
An autologous stem cell transplant (ASCT) was performed in December 1996. Conditioning was with melphalan 120 mg/m 2 and busulfan 16 mg/kg. Hematologic recovery was fast: neutrophils Ͼ0.5 × 10 9 /l and platelets Ͼ50 × 10 9 /l were reached after 12 and 13 days, respectively. The aplasia period was complicated by a short-lasting febrile episode and mucositis of WHO grade IV. Two infective episodes and transient thrombocytopenia occurred within 4 months after ASCT.
On evaluation in the 6th month after ASCT, the M component was not detected on serum immunofixation, Bence-Jones proteinuria had disappeared and bone marrow biopsy showed no excess of plasma cells and a polyclonal staining with anti-k antibody. Amyloid deposit was still detected on bone marrow biopsy. The complete response was maintained on clinical and histological evaluation in the 12th and 18th month after ASCT. The arthralgias and paresthesia had ceased and she had no need of analgesic drugs. The symptoms and signs related to amyloidosis have been progressively improving during the 22 months followup after ASCT. The macroglossia decreased particularly in the anterior two-thirds of the tongue, improving the dysphagia; purpura on the face and trunk have virtually resolved (Figure 2 ). The liver is no longer palpable and the serum alkaline phosphatase has returned to the normal range.
Discussion
The initial experiences of autotransplant in AL amyloidosis which were reported in the literature were limited to single cases. In 1993, Majolino et al 5 published the case of a 53- Figure 2 The patient at the last follow-up in October 1998. The picture shows the reduction of the purpura, whose several areas of hyperpigmentation are left and the regression of periorbital ecchymoses and lips swelling.
year-old woman with nephrotic syndrome due to renal amyloid deposits who was conditioned with busulfan and melphalan, and died from CMV pneumonia 8 weeks after reinfusion of peripheral stem cell. Response could not be evaluated, but her renal function did not worsen and the marrow plasma cell infiltration decreased. In 1998, two papers published the results of high-dose treatment in a larger series of patients. Moreau et al 6 described the results of ASCT in 21 cases of AL amyloidosis; more than half of these patients had у2 clinical manifestations. The conditioning regimen consisted of high-dose melphalan alone or in combination with 12 Gy total dose irradiation. Toxicity of the procedure was very high: 9/21 patients (43%), all suffering from amyloid involvement of two or more organs, died within the first month following ASCT because of multiorgan failure. Ten of the 12 patients with only one clinical manifestation experienced clinical improvement in damaged organs with no difference in cardiac, renal or hepatic involvement.
The experience of Comenzo et al 7, 8 in 25 patients is similar to the previous one with regard to the myeloablative regimen (melphalan), to the source of the reinfused stem cells (peripheral blood) and to the features of the patients enrolled (same median age of 46 years, 68% of cases with у2 clinical manifestations). However, the early mortality was much lower (13% within 100 days of ASCT) than that reported by Moreau. Improvement in clinical function of involved organ was reported in two thirds of patients, including five patients with autonomic and peripheral polyneuropathies. Complete remission of the plasma cell clonal disorder (normal bone marrow biopsy and no M component on serum and urinary immunofixation) was reached in a larger group of patients than in Moreau's report (62% vs 30%).
The patient described in our paper had amyloid involvement of the liver but no overt cardiac or renal disease. Neuropathy was limited to the median nerves. The peculiar feature of this patient was the diffuse vascular and soft tissue amyloid infiltration that caused purpura, easy bruising, swelling of the tongue, lips and vocal cords. She underwent ASCT with a fast hematological recovery and no severe transplant-related complications. To our knowledge, this is the first report of regression of vascular and soft tissue infiltration, which, even if they are not lifethreatening, have a social impact and worsen quality of life. Moreover, this patient experienced resolution of the liver involvement, documented by return to normal hepatic size, normalization of alkaline phosphatase, and complete and persisting remission of the clonal plasma cell disorder.
In conclusion, high-dose treatment should be considered in selected patients with AL amyloidosis, because it can achieve a reduction in plasma cell burden and improve symptoms and signs of organ amyloid involvement.
